One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Europe Clinical Trials Market

[ 英語タイトル ] Europe Clinical Trials Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0088741
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 80
Category : Healthcare and Pharmaceuticals
Study Area : Europe
Report format : PDF
Sales price option (consumption tax not included)
Single User USD3750 / Question Form
5 User USD4250 / Question Form
Enterprise User USD7000 / Question Form
 - Clinipace Worldwide
- Eli Lilly and Company
- Novo Nordisk
- Parexel
- Pfizer Inc.
- Pharmaceutical Product Development LLC
- F. Hoffmann-La Roche AG
- Sanofi

[Report Description]

Factors that are responsible for the growth of the European clinical trials market include high R&D spending of the pharmaceutical industry and the increasing prevalence of diseases.

- Another driving factor is the increasing focus on rare diseases and multiple orphan drugs in the pipeline. As rare diseases have considerably low prevalence rate, as compared to other diseases, drug manufacturers were previously not interested in developing drugs for rare diseases, due to the low earnings in this category. However, the situation has changed currently, as companies are increasingly focusing on cures for rare diseases, specifically in developed countries.
- The push from different governments has motivated the small, medium, and large players to enter into orphan drug development. Thus, there are multiple drugs in the pipeline. Additionally, the orphan drug presents an avenue of high profit to the leading pharmaceutical companies working in a low CAGR market. As a result, Novartis, GlaxoSmithKline, and Pfizer (among others) have entered this field.

Key Market Trends

The Phase III Segment is Expected to hold the Major Revenue Share

Phase III is one of the most critical phases assessing the effectiveness of the new intervention, as well as its value in clinical practice. As per the EU Clinical Trials Register, a total number of 12,748 studies are currently in Phase III trials in European countries.

In phase III, the drug or the treatment is tested in large groups of people, ranging from 1,000 to 3,000 participants. These trials are conducted to confirm and expand on the safety and effectiveness results from Phase I and II trials, to compare the drug to standard therapies for the disease or condition being studied, and to evaluate the overall risks and benefits of the drug.

Competitive Landscape

The European clinical trials market is competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising need for new drugs and treatments, advances in healthcare, and an increasing number of new diseases, it is expected that few smaller players will enter the market and may hold a substantial share in the near future. Some of the major players of the market are Eli Lilly and Company, Pfizer Inc., Pharmaceutical Product Development LLC, Novo Nordisk, and Sanofi, among others.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 High R&D Spending of the Pharmaceutical Industry
4.2.2 Increasing Prevalence of Diseases
4.2.3 Focus on Rare Diseases and Multiple Orphan Drugs in Pipeline
4.3 Market Restraints
4.3.1 Lower Healthcare Reimbursement in Developing Countries
4.3.2 Stringent Regulations for Patient Enrollment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Phase
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.1.4 Phase IV
5.2 By Design
5.2.1 Treatment Studies Randomized Control Trial Adaptive Clinical Trial Non-randomized Control Trial
5.2.2 Observational Studies Cohort Study Case Control Study Cross Sectional Study Ecological Study
5.3 Geography
5.3.1 Europe Germany United Kingdom France Italy Spain Rest of Europe

6.1 Company Profiles
6.1.1 Clinipace Worldwide
6.1.2 Eli Lilly and Company
6.1.3 ICON PLC
6.1.4 Novo Nordisk
6.1.5 Parexel
6.1.6 Pfizer Inc.
6.1.7 Pharmaceutical Product Development LLC
6.1.8 IQVIA
6.1.9 F. Hoffmann-La Roche AG
6.1.10 Sanofi




Recommended reports